Mental health inquiry on troubling path
A lawyer representing more than 120 bereaved families at a mental health public inquiry has warned the hearing is in danger of heading "down a troubling path".
The Lampard Inquiry is looking into the deaths of more than 2,000 people under mental health services in Essex between 2000 and 2023.
Nina Ali, partner at Hodge Jones & Allen solicitors, said some of the evidence during May's hearings in central London had left their clients "with an overwhelming sense of dissatisfaction".
Baroness Lampard, in the chair for the inquiry, said she was "profoundly conscious" of the disappointment felt by some of the core participants.
The majority of mental health services in Essex are now run by Essex Partnership University NHS Foundation Trust (EPUT).
The trust was due to give evidence at the inquiry on Wednesday relating to its use of Oxevision – a monitoring and alert system used on some of its wards and units to make sure patients are not harming themselves.
A late submission of evidence by EPUT, which contained substantial changes to its previous position, was described as "highly unsatisfactory" by the inquiry's chief counsel and a decision was taken to postpone the hearing.
Baroness Lampard said she was "extremely dissatisfied" with EPUT, which apologised afterwards for not sharing details sooner.
"EPUT's late submission of the Oxevision evidence - despite being aware of the deadlines - shows a blatant disregard for the families," Ms Ali said.
"We are concerned that if this behaviour is tolerated, it will send the inquiry down a troubling path."
Melanie Leahy campaigned for more than a decade for a public inquiry following the death of her 20-year-old son Matthew in 2012 at the Linden Centre mental health unit in Chelmsford.
"Baroness Lampard has vowed to 'seek out' the truth during this inquiry but I fear history will repeat itself and she will come up against the various brick walls I have over the last 13 years of campaigning for the truth," she said.
"I sincerely hope this is not the case.
"EPUT's decision to submit evidence late… is not behaviour that shocks me.
"The total disregard for the families, who should always be at the heart of this inquiry, is indicative of how we have been treated by the trust for over a decade."
Sally Mizon - whose husband Mark Tyler died in 2012 - said she was "extremely disappointed" with the level of progress of the Lampard Inquiry so far.
Mr Tyler shot his mother and then himself in Crays Hill near Basildon in September 2012. An inquest into his death heard he had attended a mental health assessment just weeks earlier, and that he had been "repeatedly ignored and let down by the system he consistently asked for help from".
"I hope the next stage of the inquiry will quash my fears of a cover-up and demonstrate that it is a collaborative investigation which proves a clear desire to keep us - the families - at the heart of the process," Ms Mizon said.
Addressing the inquiry on Monday, Baroness Lampard said she was "profoundly conscious that some core participants may be disappointed with the decision I have made to postpone hearing evidence in relation to Oxevision".
"My decision… should not be viewed in any way as enabling EPUT to avoid answering questions about its use of Oxevision or to evade responsibility - quite the reverse," she added.
"I wish to make it clear that I am extremely dissatisfied with EPUT's late submission of evidence. I have said previously, and I repeat, that I will not hesitate to use my statutory powers to compel evidence should this be required."
A spokesperson for EPUT confirmed to the BBC that its new standard operating procedure regarding the use of Oxevision came into effect on 7 May.
"We have to react to changing guidance around many areas of the delivery of care and have been reviewing our operating procedure for the use of Oxevision remote monitoring technology following new NHS guidance which was released in February 2025," the spokesperson said.
"The review has been completed and the new standard operating procedure is now in place.
"We apologise to Baroness Lampard and anyone impacted that we didn't share details of changes sooner."
The trust's chief executive Paul Scott has apologised for deaths under his trust's care.
Giving evidence to the inquiry, Mr Scott said the testimonies of bereaved relatives had been "brave, powerful and heartbreaking".
The next evidence sessions at the inquiry are due to be held in July at Arundel House
Follow Essex news on BBC Sounds, Facebook, Instagram and X.
Mental health boss 'heartbroken' by patient deaths
Charity boss slams 'reprehensible' health trusts
'The NHS at its worst', ex-ombudsman tells inquiry
What is the Lampard Inquiry and what could it change?
Lampard Inquiry

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Entrepreneur
an hour ago
- Entrepreneur
Estee Lantos Launches Refined Masterclass to Help People Slow Biological Aging by Transforming Stress from Within
Learn how nervous system regulation and optimised, yet not rigid lifestyle practices such as sleep, nourishment, movement can help you feel your best and slow down ageing, beginning June 1st You're reading Entrepreneur United Kingdom, an international franchise of Entrepreneur Media. Estee Lantos, a respected voice in biohacking and holistic wellness, is proud to unveil the revamped version of her "Biohack with Nervous System-first Masterclass – a transformative experience designed to help participants understand the factors that influence their biological age and how they can respond to life with more ease & connection. The masterclass is available online from June 1st and is priced at just £50. This 90-minute pre-recorded training is a powerful entry point into Estee's broader wellness ecosystem, offering education and practical tools to to help people feel better, function optimally, and maintain youthful vitality. Estee Lantos "Our culture teaches us to manage stress after it happens. But what if you could train your body to respond differently in the first place?" says Estee. "The key to longevity isn't just in what you eat or how you sleep—it lies in a holistic approach that begins with how effectively you can guide your nervous system back to safety, and live from a place of ease. Inside the Masterclass: A Step-by-Step Guide to Real Change Participants will learn: The science of stress and how the nervous system responds How to create safety within the body through cues and awareness Lifestyle pillars including sleep and recovery, cycle aligned movement and nourishment, cellular health and some other health optimisation practices that actually nourish you. A softer, more sustainable approach to wellness – focused on connection and community But the masterclass is just the beginning. Estee offers a range of transformational services to support individuals at every stage of their wellness journey. Her practice is built around two other core offerings: Somatic Work Personalized support through 1:1 sessions online or in-person sessions, where clients are guided through TRE (Tension, Stress & Trauma Release Exercise) – a body-based practice to release stored stress and reset the nervous system. Ideal for those needing deeper emotional and physical grounding. The Path: 6-Month Transformational Program Estee's signature, high-touch program that includes personalized biological age testing (in partnership with GlycanAge), customized plans, holistic protocols, and continuous coaching. It's an intimate experience built around accountability, deep change, and long-term vitality. Why It Matters Today, many people assume they are living healthy lives – but when they take a biological age test, they're shocked to discover their body is aging faster than expected. Estee's mission is to close this gap through a gentle, scientific, and highly personalised approach. The masterclass not only educates but empowers people to take back control of their health & longevity. The Refined Masterclass is now live. To learn more and join the experience, visit Estee's website or follow her on Instagram
Yahoo
an hour ago
- Yahoo
L'Oréal acquires a majority stake in British skincare brand Medik8
L'Oréal has acquired a majority stake in the UK's Medik8 as it seeks to expand its position in the skincare market, the French beauty giant confirmed on Monday. As part of the deal, private equity firm Inflexion will remain a minority shareholder, and the current management committee will also stay in their roles. The cost of the stake is officially undisclosed, although the Financial Times reported last week that the potential deal was worth around €1bn. L'Oréal's share price was roughly unchanged on the news. 'We are delighted to welcome Medik8 to the L'Oréal family,' said Cyril Chapuy, President of L'Oréal LUXE. 'As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio,' he added. L'Oréal has been seeking to capitalise on the boom in science-driven skincare, partly driven by social media influencers. Brands already under its 'Dermatological Beauty Division' include La Roche-Posay, Cerave, Vichy, Skinceuticals, and Skinbetter Science. Related L'Oréal acquires Galderma stake and targets the injectables market The Body Shop goes into administration, with hundreds of UK jobs at risk This unit brought in over €7bn in revenue in 2024, representing an almost 10% year-on-year rise, making it L'Oréal's fastest-growing division. Seeking to expand its portfolio, L'Oréal bought soap maker Aesop in 2023, and Korean beauty brand Dr.G in December. Last year, L'Oréal also acquired a 10% stake in skincare firm Galderma, as well as acquiring the beauty licence for Miu Miu. At the time of the Galderma deal, the French firm said it was 'increasingly investing in a more holistic approach, spanning the entire beauty routine' — thereby 'anticipating and intercepting the signs of skin ageing'. Medik8, founded in 2009, specialises in anti-ageing treatments and was bought by UK-based private equity firm Inflexion in 2021. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Medscape
2 hours ago
- Medscape
Two UK Cardiology Trials Struggle to Recruit Patients
MANCHESTER — Two ongoing cardiology trials in the UK are facing substantial recruitment challenges, researchers reported at the British Cardiovascular Society (BCS) Annual Conference 2025. The BRITISH study has enrolled fewer than one-third of its targeted 2504 patients over 2 years. Meanwhile, CRAAFT-HF has recruited just 22 of its 1200-patient goal since launching in December 2024. 'We are running behind schedule,' said Andrew Flett, a consultant cardiologist at University Hospital Southampton NHS Trust and principal investigator for BRITISH. 'We're running at about 50% of where we should be, and we're putting in every effort to try and improve that.' CRAAFT-HF's chief investigator Pier Lambiase, professor of cardiology at University College London, said that the trial's eligibility criteria were 'evolving' and being adjusted to boost recruitment. Entry Criteria Adjustments for CRAAFT-HF CRAAFT-HF is comparing surgical versus medical ablation of atrial fibrillation (AF) in people with heart failure and a reduced ejection fraction (EF) of 50%. The trial is still in its vanguard phase, with 14 centres open for an average of 4.5 months. The aim was to have at least 120-215 patients recruited across 10 sites within the first year. Professor Pier Lambiase Despite a large potential pool of patients with heart failure and AF seen in clinics, 'only about 5% are referred for ablation', Lambiase said. To improve recruitment, proposed changes include: Broadening the definition of AF to include paroxysmal and persistent types (up to 3 years' duration), confirmed by ECG, Holter monitoring, or cardiac implantable electronic devices (CIEDs). Relaxing inclusion thresholds for New York Heart Association (NYHA) class and LVEF thresholds. Removing NT-proBNP and medication optimisation criteria for trial eligibility. 'We've learned very quickly that this is threatening the trial,' Lambiase said. 'It's a lot of work to get the patient recruited, start optimal therapy, repeat the [echocardiogram], make sure they're still in the trial.' He estimated the revised criteria could have added 62 patients – tripling current enrolment. Lambiase remains optimistic, citing remote follow-up protocols and international collaboration plans with centres in Canada, Australia, Sweden, and Spain. Expanding the pool of associate principal investigators to include nurses and pharmacists may also help accelerate recruitment. The BRITISH Study The BRITISH study, active since 2023, is running at 46 of its planned 50 UK sites and actively recruiting. Ongoing since 2023, 46 out of the planned 50 sites are actively recruiting patients into the BRITISH study. It aims to determine whether scarring detected via cardiovascular magnetic resonance (CMR) is associated with reduced mortality in patients with nonischaemic cardiomyopathy and severe systolic heart failure (LVEF ≤35%) who receive implantable cardioverter defibrillators (ICDs). Andrew Flett Flett reported that of the 390 patients enrolled so far: Half were recruited within one year of diagnosis. Just under 20% were recruited within 6 months. Almost two-thirds had NYHA Class II heart failure. 38% had AF. Flett said this is 'the best-treated heart failure population in a heart failure trial that I'm aware of', noting high rates of evidence-based therapy: 93% on beta-blockers. 97% on antihypertensives. 92% on sodium-glucose cotransport 2 (SGLT2) inhibitors. 88% on mineralocorticoid receptor antagonists. The median age is 66 years. Most participants are White (93%) and male (80%). Addressing Gender Disparities in Trial Recruitment The under-representation of women — just 20% of the current cohort — is 'a major source of concern', Flett told Medscape News UK . The BCS and the British Heart Foundation Clinical Research Collaborative have previously highlighted the need to include more women in clinical trials. A consensus paper in the journal Heart , published at the start of the BCS annual conference, outlined strategies to improve female participation. However, Flett noted that nonischaemic cardiomyopathy is more common in men. 'We're going to recruit the patients that are there, and most of them are men,' he said. If we had 'the luxury of plenty of patients, we could obviously hold back on male recruitment', he added. Efforts are also underway to increase the number of female principal investigators (PIs). Currently, just 6 of the 46 site PIs are women. Recruitment could take another 2-3 years at the current pace. Plans are being considered to open additional sites in Australia and to remind UK centres of the importance of balanced gender recruitment. The BRITISH and CRAAFT-HF studies are funded by the British Heart Foundation. Flett and Lambiase had no conflicts of interest to disclose.